Comparative Pharmacology
Head-to-head clinical analysis: EPANED versus VAZCULEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANED versus VAZCULEP.
EPANED vs VAZCULEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Vazculep is a direct-acting vasoconstrictor that stimulates alpha-adrenergic receptors in vascular smooth muscle, causing peripheral vasoconstriction and increased blood pressure.
0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.
5 mg IV bolus followed by 2.5 mg/hour continuous IV infusion; titrate to mean arterial pressure ≥65 mmHg. Maximum infusion rate: 40 mg/hour.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and 15-20 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is 12 hours. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 24 hours. Dose adjustment is recommended for CrCl <30 mL/min.
Renal excretion of unchanged drug accounts for approximately 30-40% of elimination; biliary/fecal excretion accounts for 50-60% as metabolites and unchanged drug.
Renal excretion of unchanged drug accounts for 70% and fecal/biliary excretion accounts for 30%. Approximately 15% of the dose is excreted as glucuronide conjugate in urine.
Category C
Category C
Vasopressor
Vasopressor